A Changing Paradigm: The Swift Expansion of Adult Living Donor Liver Transplantation for MASH Cirrhosis
This retrospective analysis of US data from 2000 to 2024 reveals that metabolic dysfunction–associated steatohepatitis (MASH) has become the fastest-growing indication for adult living donor liver transplantation, increasing 5.4-fold and surpassing other etiologies, thereby highlighting limitations in the current MELD-based allocation system and the need to address donor eligibility barriers to ensure equitable access.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
When a liver fails, the body loses its ability to filter toxins and process nutrients, a condition that can become fatal without a replacement organ. For decades, the standard path to a new liver has been waiting for a deceased donor, a process governed by a scoring system that ranks patients based on how sick they are. However, this system has a blind spot: it often fails to capture the true urgency of patients whose livers are failing due to metabolic issues or long-term alcohol use, even when their scores suggest they are stable. In these cases, a living donor liver transplant offers a lifeline. This procedure involves a healthy person, usually a family member, donating a portion of their liver to a patient in need. The donated section grows back in both the donor and the recipient, making it a unique solution that bypasses the waiting list. As the types of liver disease affecting the population have shifted over the last twenty-five years, the need for this alternative has evolved, raising questions about who is getting these transplants and why.
Researchers at the University of Virginia and other institutions set out to map these changes by looking at nearly 7,700 adult living donor liver transplants performed in the United States between the years 2000 and 2024. They analyzed data from the national registry that tracks every organ transplant in the country, focusing on the reasons patients needed a new liver and the characteristics of the people who donated. Their work reveals a dramatic shift in the landscape of liver disease. In the early 2000s, the most common reason for a living donor transplant was hepatitis C, a viral infection. Today, that has changed completely. The fastest-growing group of patients receiving these transplants are those with metabolic dysfunction-associated steatohepatitis, a condition often linked to obesity and diabetes where the liver becomes inflamed and scarred. The proportion of transplants for this condition has risen more than five times over the study period, moving from a small fraction of cases to representing nearly one-third of all living donor transplants by 2024.
While the number of transplants for metabolic liver disease has surged, the trends for other conditions tell a different story. The sharp decline in hepatitis C cases mirrors the success of new medicines that can cure the infection, removing the need for transplants in many patients. In contrast, the number of transplants for alcohol-associated liver disease has remained relatively steady, even though the total number of people on the waiting list for this condition has grown. This stability suggests that patients with alcohol-related liver failure are often receiving deceased donor organs, perhaps because their condition leads to higher scores on the standard sickness scale, making them a priority for the available organs from deceased donors. Meanwhile, patients with metabolic liver disease often fall through the cracks of that same scoring system, making the living donor option increasingly critical for their survival.
The study also uncovered significant differences in who is donating the livers for these different groups. For patients with metabolic liver disease, the pool of eligible family members is often smaller. Because the condition is linked to shared lifestyle factors like diet and weight, many potential relatives, including spouses and siblings, may have similar liver issues or higher body weights that disqualify them from donating. As a result, patients with metabolic liver disease are more likely to receive a liver from an adult child or an unrelated donor who does not share those specific genetic or environmental risks. In contrast, patients with other types of liver disease, such as those affecting the bile ducts, are more likely to receive donations from spouses or siblings. The data also highlights a racial disparity in unrelated donations; while most living donors and recipients share the same race, this is far less common for minority groups, where finding an unrelated donor of the same background is significantly harder.
The researchers found that patients with metabolic liver disease often have higher sickness scores at the time of their transplant compared to those with other causes, yet they still rely heavily on living donors. This points to a limitation in how the current system prioritizes patients for deceased donor organs. The scoring system does not always reflect the rapid decline or the specific risks faced by those with metabolic liver disease, leading to a situation where living donation becomes the primary path to a cure. The authors note that while the data clearly shows these trends, it cannot fully explain why some patients are rejected as donors or why certain groups have less access to living donors. What is clear, however, is that the face of liver transplantation in America is changing. As metabolic liver disease becomes the dominant driver of organ failure, the medical community must address the barriers that prevent eligible family members from donating, ensuring that the lifeline of living donation remains open to all patients, regardless of the cause of their illness.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.